Clinical trial
Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other…
NCT00498992 · Ingalls Memorial Hospital, Other · Unknown status
Key facts
| NCT number | NCT00498992 |
|---|---|
| Title | Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer |
| Official title | Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients |
| Lead sponsor | Ingalls Memorial Hospital, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Dietary Supplement |
| Interventions | collagen/aloe vera/vitamin E/lidocaine topical hydrogel |
| Enrollment | 20 |
| Start date | Jul 1, 2006 |
| First posted | Jul 11, 2007 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: